Neurology biomarker firm C2N Diagnostics is accelerating its test development efforts with the aim of commercializing protein markers for the early detection of Alzheimer's as well as for use as primary endpoints in Phase III clinical trials of therapies for the disease.
Dutch gene therapy firm UniQure and academic collaborators have been awarded a three-year grant worth €2.5 million ($3.2 million) from the European Commission to develop a treatment for Huntington’s disease that combines RNAi and gene replacement.
KineMed has entered into a collaboration with Isis Pharmaceuticals and CHDI Foundation that will use KineMed's biomarker platform in support of Isis' antisense therapeutics program for Huntington's disease.
Diagnostic biomarker firm KineMed said this week that it has signed a deal to provide its translational biomarker platform to Isis Pharmaceuticals and CHDI Foundation for use in their partnership developing an antisense-based treatment for Huntington's disease.
Dutch gene therapy firm UniQure threw its hat into the RNAi ring this week, announcing that it has picked up non-exclusive access to Benitec Biopharma's proprietary expressed RNAi technology for use with its nascent Huntington's disease program.
Researchers from the University of Texas Southwestern Medical Center this month published new data describing the mechanism by which mismatch-containing double-stranded RNAs preferentially inhibit the mutant gene that causes Huntington's disease over the wild-type gene.